CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

AIMS: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) and their early change as predictor of benefit. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607728/
https://www.ncbi.nlm.nih.gov/pubmed/33193825
http://dx.doi.org/10.1177/1758835920952994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607728/
https://www.ncbi.nlm.nih.gov/pubmed/33193825
http://dx.doi.org/10.1177/1758835920952994

Ejemplares similares